AI-Powered Drug Delivery: METiS TechBio Partners with Boulevard Bio for Innovative Therapeutics#METiS_TechBio#Boulevard_Bio#trispecific_T-cell
AI-Powered Drug Delivery: METiS TechBio Partners with Boulevard Bio for Innovative Therapeutics
METiS TechBio and Boulevard Bio have signed a global license deal for a cutting-edge trispecific T-cell engager, revolutionizing drug delivery systems.
third-news.com
June 30, 2026 at 9:39 AM
AI-Powered Drug Delivery: METiS TechBio Partners with Boulevard Bio for Innovative Therapeutics#METiS_TechBio#Boulevard_Bio#trispecific_T-cell
METiS TechBio Unveils Groundbreaking Cardiomyocyte Delivery Data at CRS 2026#China#Beijing#Gene_Editing#METiS_TechBio#cardiomyocyte
METiS TechBio Unveils Groundbreaking Cardiomyocyte Delivery Data at CRS 2026
METiS TechBio showcases innovative data on cardiomyocyte delivery at CRS 2026, unveiling advancements in targeted gene therapies using AI-driven technology.
third-news.com
May 20, 2026 at 11:14 AM
METiS TechBio Unveils Groundbreaking Cardiomyocyte Delivery Data at CRS 2026#China#Beijing#Gene_Editing#METiS_TechBio#cardiomyocyte
Significant Advancements in mRNA Cancer Treatment by METiS TechBio Unveiled in Prestigious Journals#METiS_TechBio#MTS-105#MTS-107
Significant Advancements in mRNA Cancer Treatment by METiS TechBio Unveiled in Prestigious Journals
METiS TechBio announces groundbreaking findings on its candidates MTS-105 and MTS-107 in leading journals, showcasing AI-driven innovation in cancer therapy.
third-news.com
December 16, 2025 at 11:16 AM
Significant Advancements in mRNA Cancer Treatment by METiS TechBio Unveiled in Prestigious Journals#METiS_TechBio#MTS-105#MTS-107